U.S. FDA compliance issues at Pithampur and Monroe plants
Pithampur plant under FDA discussion; Monroe plant awaiting inspection. Delays could impact U.S. launch timelines.
high · analyst_question
Glenmark Pharmaceuticals Limited — Q4 FY25
Glenmark's Q4 FY25 consolidated revenue grew 6.3% YoY to INR 3,256 crore, with full-year revenue up 12.8% to INR 13,322 crore.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Diabetes portfolio erosion in India
Remogliflozin and Teneligliptin, which contributed ~60% of diabetes sales, faced generic competition; new launches (Lirafit, Empagliflozin) yet to fully offset decline.
medium · management_commentaryDelayed U.S. launches and lack of meaningful approvals
North America revenue declined 5.4% due to back-ended launches; Flovent and nasal spray approvals may slip further.
medium · data_observationIGI licensing deal uncertainty
ISB 2001 licensing deal is critical to fund IGI's $70M annual burn; any delay could pressure margins.
high · management_commentary